Otsuka Pakistan Limited (OPL) is engaged in the manufacturing, marketing and distribution of intravenous (IV) infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company's activities are focused on the manufacturing of IV Solutions and marketing them. The Company provides international solutions and medicines to doctors, hospitals and pharmacies. The Company's products include intravenous solutions, cardiac stents, clinical nutrition and therapeutic drugs. Its intravenous solutions include electrolyte solutions, standard solutions, ampoules and others. The Company offers various cardiac stents, such as firebird, jive, mustang and tango. The clinical nutrition products include aminoleban oral, aminovel 600, pan-amin g, pan-amin sg and aminoleban injection. Pletaal is the therapeutic drug of the Company. The Company's subsidiary is Messrs Otsuka Pharmaceutical Company Limited.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.